- Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
- Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
- Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
- Dr. Reddy’s Q4 & Full Year FY24 Financial Results
- Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
- Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
More ▼
Key statistics
On Friday, Dr Reddy's Laboratories Ltd (RDY:NYQ) closed at 71.36, -8.18% below its 52-week high of 77.72, set on Feb 23, 2024.
52-week range
Open | 71.76 |
---|---|
High | 71.98 |
Low | 71.26 |
Bid | 69.95 |
Offer | 72.77 |
Previous close | 70.35 |
Average volume | 280.12k |
---|---|
Shares outstanding | 166.53m |
Free float | 166.00m |
P/E (TTM) | 17.19 |
Market cap | 11.49bn USD |
EPS (TTM) | 4.00 USD |
Annual div (ADY) | 0.4792 USD |
---|---|
Annual div yield (ADY) | 0.69% |
Div ex-date | Jul 28 2023 |
Div pay-date | Aug 11 2023 |
Data delayed at least 15 minutes, as of Jun 08 2024 00:00 BST.
More ▼